1H 2024: Presentation of final results of Phase 1 azenosertib + chemotherapy trial in R/R osteosarcoma at 2024 ASCO Annual Meeting 2H 2024: Presentation of final results of Phase 1b azenosertib monotherapy trial in solid tumors; Topline data from Phase 1/2 MAMMOTH azenosertib + PARP inhibitor and azenosertib monotherapy trial in platinum resistant ovarian cancer in partnership with GSK; Presentation of initial data from Phase 1 azenosertib + BEACON regimen trial in BRAF mutant metastatic colorectal cancer in partnership with Pfizer; Initial data from Phase 1 azenosertib + ZN-d5 trial in R/R AML; Additional details on design of planned registration-enabling trial of azenosertib in PSOC in the 1L maintenance setting. 1H 2025: Topline data from registration-enabling Phase 2 DENALI study of azenosertib monotherapy in platinum resistant high-grade serous ovarian cancer 2H 2025: Topline data from registration-enabling Phase 2 TETON study of azenosertib monotherapy in recurrent or persistent USC. 2025: Initiate registration-enabling trial of azenosertib in PSOC in the 1L maintenance setting. 2026: First NDA for azenosertib in a gynecologic malignancy
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zentalis Pharmaceuticals Announces Executive Financial Transition
- Zentalis Pharmaceuticals to Present at Upcoming Conferences
- Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
